Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking significant advancements in their drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets multiple myeloma cells by recruiting and activating T cells [1] - There are currently no similar drugs approved for market in China [1] - The total research and development investment for the SHR-9539 injection project has reached approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBNE3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - This drug has strong substrate degradation capabilities and potential advantages in overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The total research and development investment for the HRS-3738 tablet project has reached approximately 63.63 million yuan [1]